Brought to you by 
Wilex licenses Centocor's G250 cancer mAb
Oct 1999
Executive Summary
Munich-based cancer therapeutics start-up Wilex Biotechnology GMBH has licensed exclusive worldwide rights to Centocor's Phase I G250 monoclonal antibody to determine its therapeutic potential in renal cancer applications. Centocor has the option to market the product in the US, upon which it will pay Wilex an up-front payment in addition to milestones and profits on sales.
Deal Industry
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Wilex licenses Centocor's G250 cancer mAb
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice